The Carlo Denegri Foundation is a non-profit organization of social benefit (ONLUS) founded in 1987 in Turin from an initiative of Gustavo Denegri, to honor the memory of his father Carlo.

 

The Carlo Denegri Foundation works with the aim of promoting research in the field of infectious diseases of viral etiology, involving in its activities the district Hospital Amedeo di Savoia in Turin.

In the context of its past activities, the Carlo Denegri Foundation has contributed to research projects dedicated to broadening the knowledge for the prophylaxis and treatment of infectious diseases in the Piedmontese area and their clinical, social and sociological classification. It has also allowed researchers of the Turin area to improve their knowledge in the field through training placements in prestigious research centers abroad.

Currently, the Carlo Denegri Foundation has signed an agreement with the Foundation IRCCS Policlinico San Matteo di Pavia, supporting a proposed scientific and clinical research focused on the control of viral infections in pregnancy and intransplant patients, particularly from Cytomegalovirus (CMV). In the case of transplant patients, we intend to assist in the assessment of virological tests virus-specificimmune response in order to operate on patients who did not immediately restore theimmune system functions in post-transplant. With regard to viral infections during pregnancy, it is proposed to identify maternal and fetal prognostic factors critical in order to reduce the frequency of transmission to the fetus and the birth of babies sick.

The Carlo Denegri Foundation also supports a project of scientific and clinical research at the University of Siena focused on the neurological control of infectionscaused by arboviruses, transmitted by sand flies or mosquitoes. In particular, it is to create and optimize cost and rapid molecular tests for diagnosis of infection with Toscana virus, West Nile and Chikungunya. These viruses are considered emerging viruses because they have started to spread in our country and represent a seriousthreat to public health. In parallel, the development of new serological tests for theindirect diagnosis of infection by some of these viruses, using recombinant viralproteins or virus-specific synthetic peptides capable of interacting with specific antibodies.